A Phase 1 interventional study of iC9-CAR.B7-H3 T cells therapy in Brain Tumor, High Grade Glioma and Glioblastoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by UNC Lineberger Comprehensive Cancer Center · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,446 studies in Brain Neoplasms with a site in United States — 234 open to participants now, 354 under way, 18 of them phase 3. Brain Neoplasms · United States.
Among the 1,446 studies in Brain Neoplasms with a site in United States, this one is the 523rd largest by planned enrollment of the 1,191 interventional ones that give a count, is one of 55 that started in 2026, is one of 417 in phase 1, reaches primary completion later than 299 of the 352 other live ones, and was the 1,445th registered.
2,443 studies on the registry are indexed under Brain Neoplasms; 545 are open to participants now.
Browse Brain Neoplasms studies →234 of the 1,446 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Brian J.Gill · Sites in United States
Ages 22–65
Stanford University · Sites in United States
Ages 6 mo–25 yrs
University of California, San Francisco · Sites in United States
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
University of Florida · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,446 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 554 · Phase 2 522 · Phase 3 72 · Phase 4 18
First in 1979; this study’s year is marked. 55 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is close to the median of 40 across 1,834 interventional studies indexed under Brain Neoplasms.
Median enrollment 30 across the 1,191 interventional studies, 76 across the 191 observational. Of the 994 that completed or were terminated, 355 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
221 of 1,446 have an industry lead sponsor. The 10 most frequent:
UNC Lineberger Comprehensive Cancer Center is the lead sponsor of 431 studies on the registry; 96 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
UNC Lineberger Comprehensive Cancer Center has 8 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
140 of the studies in Brain Neoplasms with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT03741673Phase 3M.D. Anderson Cancer CenterPre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases | 2027-01-31 |
| NCT05438212Phase 3NRG OncologyComparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | 2027-03-16 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT00950001Phase 3M.D. Anderson Cancer CenterStereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases | 2027-04-30 |
Add all 140 to your calendar (.ics) → With an account.
Among the 1,446 studies in Brain Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
LCCC 2534-ATL is an early-stage (Phase 1), single-center clinical study evaluating the safety of CAR T-cell therapy in children and adults with high-grade gliomas (HGGs), which are aggressive brain cancers.
The treatment, called iC9-CAR.B7-H3 T cells, uses modified immune cells designed to recognize and attack cancer cells with a protein called B7-H3. The treatment also includes a safety switch (iC9) designed to help stop the modified cells if serious side effects occur.
Earlier studies of B7-H3-targeted CAR T-cell therapy have shown encouraging safety results, with some patients experiencing tumor shrinkage. This study will further evaluate the safety and tolerability of the treatment in children and adults with high-grade gliomas type brain tumors.
The study will use a 3+3 dose-escalation design to evaluate increasing doses and identify the safest appropriate dose. The results will help determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D), which is the dose selected for further study.
Participants who qualify will have blood collected to produce the modified T cells. Three treatment doses will be administered two weeks apart. Additional doses may be given.
Participants will be monitored for 15 years after treatment ends or is discontinued to assess potential long-term side effects related to genetic modification of the cells.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet the age requirements at consent/assent:
Histologically or radiographically diagnosed high-grade glioma, including:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult participants with High-Grade Glioma.
Biological: iC9-CAR.B7-H3 T cells therapy
Pediatric participants with High-Grade Glioma.
Biological: iC9-CAR.B7-H3 T cells therapy
Participants receive increasing doses of genetically modified immune cells (iC9-CAR.B7-H3 T cells) to evaluate safety and determine the recommended dose for future studies.
Also known as: cellular therapy
Number of Participants Experiencing Treatment-Related Adverse Events (AEs) in adults (Cohort A).
Number of Participants Experiencing Treatment-Related Grade ≥3 Adverse Events (AEs) in adults will be classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 6.0.
Time frame: Up to 8 weeks
Number of Participants Experiencing Treatment-Related Adverse Events (AEs) in Pediatrics (Cohort B)
Number of Participants Experiencing Treatment-Related Grade ≥3 Adverse Events (AEs) in pediatric participants will be classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 6.0.
Time frame: Up to 8 weeks
Cytokine Release Syndrome in adults (Cohort A)
Cytokine Release Syndrome (CRS) will be graded according to American Society for Transplantation and Cellular Therapy (ASTCT) CRS Consensus Grading. Grade ≥ 3 Adverse Events (AEs) will be reported. Grade 1 - Mild (Symptomatic Management): Fever ≥38\^ o C, No hypotension, No hypoxia, Grade 2 - Moderate (Moderate Intervention): Fever ≥38\^ o C, Hypotension not requiring vasopressors, Hypoxia requiring low-flow nasal cannula (≤6 L/minute) or blow-by, Grade 3 - Severe (Aggressive Intervention): Fever ≥ 38\^ o C , Hypotension requiring a vasopressor with or without vasopressin, Hypoxia requiring high-flow nasal cannula (\>6 L/minute), facemask, nonrebreather mask, or Venturi mask, Grade 4 - Life-threatening (Life-sustaining intervention): Fever ≥38\^oC, Hypotension requiring multiple vasopressors (excluding vasopressin),Hypoxia requiring positive pressure (e.g. Continuous positive airway pressure, BiPAP, intubation, mechanical ventilation), Grade 5 - Death: Death.
Time frame: Up to 8 weeks
Cytokine Release Syndrome in adults Pediatrics (Cohort B)
Cytokine Release Syndrome (CRS) will be graded according to American Society for Transplantation and Cellular Therapy (ASTCT) CRS Consensus Grading. Grade ≥ 3 Adverse Events (AEs) will be reported. Grade 1 - Mild (Symptomatic Management): Fever ≥38\^ o C, No hypotension, No hypoxia, Grade 2 - Moderate (Moderate Intervention): Fever ≥38\^ o C, Hypotension not requiring vasopressors, Hypoxia requiring low-flow nasal cannula (≤6 L/minute) or blow-by, Grade 3 - Severe (Aggressive Intervention): Fever ≥ 38\^ o C , Hypotension requiring a vasopressor with or without vasopressin, Hypoxia requiring high-flow nasal cannula (\>6 L/minute), facemask, nonrebreather mask, or Venturi mask, Grade 4 - Life-threatening (Life-sustaining intervention): Fever ≥38\^oC, Hypotension requiring multiple vasopressors (excluding vasopressin),Hypoxia requiring positive pressure (e.g. Continuous positive airway pressure, BiPAP, intubation, mechanical ventilation), Grade 5 - Death: Death.
Time frame: Up to 8 weeks
Neurotoxicity in adults (Cohort A)
Neurotoxicity will be graded according to the Central Nervous System (CNS) Toxicity criteria. Grade ≥ 3 Adverse Events (AEs) will be reported. Grade 0: Normal or no change from baseline exam at start of therapy, Grade 1: Mild lethargy and/or irritability or visual, motor, or sensory symptoms without change in neurological exam, Grade 2: Moderate lethargy, disorientation, or psychosis lasting \< 48 hours or mild increase in pre-existing neurological deficit, Grade 3: \>48hours of severe lethargy, but responsive to verbal stimuli or disorientation or psychosis lasting \>48 hours, Grade 4: Coma, unresponsive to verbal stimuli, increasing neurological deficit above grade 3, evidence of herniation, development of uncontrolled seizures, intracerebral hemorrhage.
Time frame: Up to 8 weeks
Neurotoxicity in Pediatrics (Cohort B)
Neurotoxicity will be graded according to the Central Nervous System (CNS) Toxicity criteria. Grade ≥ 3 Adverse Events (AEs) will be reported. Grade 0: Normal or no change from baseline exam at start of therapy, Grade 1: Mild lethargy and/or irritability or visual, motor, or sensory symptoms without change in neurological exam, Grade 2: Moderate lethargy, disorientation, or psychosis lasting \< 48 hours or mild increase in pre-existing neurological deficit, Grade 3: \>48hours of severe lethargy, but responsive to verbal stimuli or disorientation or psychosis lasting \>48 hours, Grade 4: Coma, unresponsive to verbal stimuli, increasing neurological deficit above grade 3, evidence of herniation, development of uncontrolled seizures, intracerebral hemorrhage.
Time frame: Up to 8 weeks
Treatment-Induced Adverse Neurological Events (TIAN) in adults (Cohort A)
Treatment-Induced Adverse Neurological Events (TIAN) will be classified and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 6.0. Grade ≥3 adverse events (AEs) will be reported. TIAN severity will be assessed using the applicable CTCAE v6.0 criteria.
Time frame: Up to 8 weeks
Treatment-Induced Adverse Neurological Events (TIAN) in Pediatrics (Cohort B)
Treatment-Induced Adverse Neurological Events (TIAN) will be classified and graded per protocol-specific criteria; Grade ≥3 adverse events (AEs) will be reported. Grade 1 (mild): Headache with fever \>38°C or mild worsening of pre-existing neurological signs/symptoms causing minor functional deficits, requiring observation or symptomatic management only. Grade 2 (moderate): Moderate neurological examination changes from baseline substantially affecting function (e.g., new/worsening hemiparesis, ataxia limiting walking, or cranial neuropathies limiting eating). Grade 3 (severe): Severe neurological signs/symptoms potentially affecting critical cardiorespiratory functions, or increased intracranial pressure (ICP) \>20 mmHg responsive to intervention. Grade 4 (life-threatening).
Time frame: Up to 8 weeks
The recommended phase 2 dose (RP2D) in adults (Cohort A)
The recommended phase 2 dose (RP2D) of iC9-CAR.B7-H3 T cells will be determined using modified 3+3 dose-escalation rules. Tolerability will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 6.0, and the American Society for Transplantation and Cellular Therapy (ASTCT) criteria for cytokine release syndrome (CRS). Neurotoxicity will be assessed using the Treatment-Induced Adverse Neurological Events (TIAN) criteria.
Time frame: Up to 8 weeks
The recommended phase 2 dose (RP2D) in Pediatrics (Cohort B)
The recommended phase 2 dose (RP2D) of iC9-CAR.B7-H3 T cells will be determined using modified 3+3 dose-escalation rules. Tolerability will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 6.0, and the American Society for Transplantation and Cellular Therapy (ASTCT) criteria for cytokine release syndrome (CRS). Neurotoxicity will be assessed using the Treatment-Induced Adverse Neurological Events (TIAN) criteria.
Time frame: Up to 8 weeks
The disease control rate (DCR) in adults (Cohort A)
The disease control rate (DCR) is the proportion of subjects who achieve a complete response (CR), partial response (PR), or stable disease (SD), as defined in the protocol. Complete response (CR) is defined as the disappearance of all target lesions. Partial response (PR) is defined as at least a 50% decrease in the sum of the products of the two perpendicular diameters of all target lesions compared with baseline measurements. Stable disease (SD) is defined as neither a sufficient decrease in tumor size to qualify as a partial response nor a sufficient increase to qualify as progressive disease (PD).
Time frame: Up to 2 years
The disease control rate (DCR) in Pediatrics (Cohort B)
The disease control rate (DCR) is the proportion of subjects who achieve a complete response (CR), partial response (PR), or stable disease (SD), as defined in the protocol. Complete response (CR) is defined as the disappearance of all target lesions. Partial response (PR) is defined as at least a 50% decrease in the sum of the products of the two perpendicular diameters of all target lesions compared with baseline measurements. Stable disease (SD) is defined as neither a sufficient decrease in tumor size to qualify as a partial response nor a sufficient increase to qualify as progressive disease (PD).
Time frame: Up to 2 years
Progression free survival (PFS) in adults (Cohort A)
Progression free survival (PFS) will be measured from first cell administration to progression (as defined as Progressive Disease as defined in the protocol. Complete response (CR) is defined as the disappearance of all target lesions. Partial response (PR) is defined as at least a 50% decrease in the sum of the products of the two perpendicular diameters of all target lesions compared with baseline measurements. Stable disease (SD) is defined as neither a sufficient decrease in tumor size to qualify as a partial response nor a sufficient increase to qualify as progressive disease (PD).
Time frame: Up to 2 years
Progression free survival (PFS) in Pediatrics (Cohort B)
Progression free survival (PFS) will be measured from first cell administration to progression as defined as Progressive Disease as defined in the protocol. Complete response (CR) is defined as the disappearance of all target lesions. Partial response (PR) is defined as at least a 50% decrease in the sum of the products of the two perpendicular diameters of all target lesions compared with baseline measurements. Stable disease (SD) is defined as neither a sufficient decrease in tumor size to qualify as a partial response nor a sufficient increase to qualify as progressive disease (PD).
Time frame: Up to 2 years
Overall survival (OS) in adults (Cohort A)
Overall survival (OS) will be measured from the date of initial diagnosis to date of death for any cause.
Time frame: Up to 2 years
Overall survival (OS) in Pediatrics (Cohort B)
Overall survival (OS) will be measured from the date of initial diagnosis to date of death for any cause.
Time frame: Up to 2 years
Duration of response (DOR) in adults (Cohort A)
Duration of response (DOR) will be defined as the time from documentation of Partial Response (PR) or better to progressive disease (PD). Partial response (PR) is defined as at least a 50% decrease in the sum of the products of the two perpendicular diameters of all target lesions compared with baseline measurements. Stable disease (SD) is defined as neither a sufficient decrease in tumor size to qualify as a partial response nor a sufficient increase to qualify as progressive disease (PD).
Time frame: Up to 2 years
Duration of response (DOR) in Pediatrics (Cohort B)
Duration of response (DOR) will be defined as the time from documentation of Partial Response (PR) or better to progressive disease (PD). Partial response (PR) is defined as at least a 50% decrease in the sum of the products of the two perpendicular diameters of all target lesions compared with baseline measurements. Stable disease (SD) is defined as neither a sufficient decrease in tumor size to qualify as a partial response nor a sufficient increase to qualify as progressive disease (PD).
Time frame: Up to 2 years
Feasibility of procuring and manufacturing iC9-CAR.B7-H3 T cells in adults (Cohort A)
To evaluate the feasibility of procuring and manufacturing iC9-CAR.B7-H3 T cells. Procurement feasibility will be measured as the proportion of individuals who successfully undergo procurement among those who attempt it. Manufacturing feasibility will be measured as the proportion of successfully procured individuals for whom the cells are successfully manufactured to provide three doses.
Time frame: Up to 8 weeks
Feasibility of procuring and manufacturing iC9-CAR.B7-H3 T cells in Pediatrics (Cohort B)
To evaluate the feasibility of procuring and manufacturing iC9-CAR.B7-H3 T cells. Procurement feasibility will be measured as the proportion of individuals who successfully undergo procurement among those who attempt it. Manufacturing feasibility will be measured as the proportion of successfully procured individuals for whom the cells are successfully manufactured to provide three doses.
Time frame: Up to 8 weeks
Plan to share: No
Start is estimated for Dec 2026; primary completion for Oct 2029, 34 months later.
Of 176 non-industry phase 1 interventional studies under Brain Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 34 months is below that.
Counting every sponsor, half of 204 studies reached it within 54 months; a quarter within 36 and three quarters within 84.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UNC Lineberger Comprehensive Cancer Center →